According to a new report published by Allied Market Research,
titled,"Autoimmune
Disease Therapeutics Market by Drug Class, Indication, and Sales Channel:
Global Opportunity Analysis and Industry Forecast, 2018-2025,"the
global autoimmune disease therapeutics market was valued at USD 109,833 million
in 2017, and is expected to reach USD 153,320 million by 2025, growing at a
CAGR of 4.2% from 2018 to 2025.
Autoimmune disease therapeutics include different types of drugs such as
anti-inflammatory, antihyperglycemics, NSAIDs, interferons, immune
suppressants, corticosteroids, beta-blockers, and others. The demand for
autoimmune disease therapeutics is estimated to increase during the forecast
period owing to surge in prevalence of autoimmune disease, advancement in
screening & diagnosis procedures, and wide availability of advanced
therapeutics. Moreover, strong presence of pipeline drugs such as tocilizumab,
baricitinib, certolizumab, secukinumab, etanercept, olokizumab, abatacept,
apremilast, PF-06438179, golimumab, ustekinumab, etrolizumab, tofacitinib, and
others is expected to further boost the market growth.
Based on drug class, the global
autoimmune disease therapeutics market is segmented into anti-inflammatory,
antihyperglycemics, NSAIDs, interferons, and others. Anti-inflammatory was the
major revenue contributing segment in 2017, and is expected to maintain its
dominance during the forecast period owing to increase in demand for anti-
inflammatory drugs, launch of newer anti- inflammatory drugs with the
supportive reimbursement policies for usage of advanced anti- inflammatory
drugs in some countries. Moreover, expected launch of pipeline
anti-inflammatories such as tocilizumab, certolizumab, secukinumab, etanercept,
golimumab, and others, is estimated to further influence the market growth.
Based on indication, the market is classified as rheumatic disease, type 1
diabetes, multiple sclerosis, inflammatory bowel disease, and other
indications. Rheumatic disease segment accounted for a major share in 2017 and
is expected to remain dominant during the forecast period owing to surge in
prevalence of arthritis, fibromyalgia, systemic lupus erythematosus, gout,
scleroderma, polymyalgia rheumatica and others, wide availability of advanced
therapeutics for treatment of rheumatic disease, availability of advanced
therapeutics for the treatment of these diseases.
According to sales channel, the market is segmented into hospital
pharmacies, drug stores & retail pharmacies, and online stores. Online
providers segment is expected to experience rapid growth during the forecast
period owing to rise in preference for online purchasing of drugs over the
traditional methods and increase in awareness about online pharmacy with rise
in number of internet users. On the other side, drug store & retail
pharmacy segment is estimated to be the major revenue contributor due to
massive presence of these pharmacies.
Based on indication, the rheumatic disease segment held nearly half of the
global market share in 2017, and is projected to grow at a CAGR of 5.2% from
2018 to 2025. Based on sales channel, the online stores segment is expected to
experience rapid growth and is projected to grow at a CAGR of 6.8% during the
forecast period 2018-2025. Depending on drug class, the anti-inflammatory
segment accounted for nearly half of the global market share in 2017, and is
projected to grow at a CAGR of 5.2% from 2018 to 2025. Based on region,
Asia-Pacific is expected to experience growth at the highest rate, registering
a CAGR of 6.3% during the forecast period. North America accounted for a major
market share in 2017, and is expected to remain dominant throughout the
forecast period. Higher prevalence of autoimmune disease, early diagnosis, easy
availability of advanced therapeutics, strong presence of key players,
favorable reimbursement in healthcare system, and higher number of trained
medical professionals are key drivers of the North America autoimmune disease
therapeutics market. On the other side, Asia-Pacific is expected to experience
the highest growth rate during the forecast period owing to increase in number
of target population, rise in adoption of therapeutics with development in
healthcare infrastructure.
For more information on the research report, refer to below
link:-
Contact Us:-
Ken Research
Ankur Gupta,
Head Marketing & Communications
+91-9015378249
No comments:
Post a Comment